To analyze the mechanistic basis of the increased susceptibility of BRCA2-deficient cancer cells towards TRAIL-R-targeting agents, cell cycle arrest and apoptosis were determined upon treatment with LBY135 and the results compared to those observed upon treatment with MMC. Here, BRCA2 is linked to cancer.